HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study.

AuthorsPatrice Chevallier, Francoise Huguet, Emmanuel Raffoux, Anne Etienne, Thibaut Leguay, Francoise Isnard, Nelly Robillard, Thierry Guillaume, Jacques Delaunay, Aude Charbonnier, Arnaud Pigneux, Pierre Peterlin, Marie C Bené, William A Wegener, David M Goldenberg, Hervé Dombret
JournalHaematologica (Haematologica) Vol. 100 Issue 4 Pg. e128-31 (Apr 2015) ISSN: 1592-8721 [Electronic] Italy
PMID25552705 (Publication Type: Clinical Trial, Phase II, Letter, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Monoclonal, Humanized
  • Sialic Acid Binding Ig-like Lectin 2
  • epratuzumab
  • Vincristine
  • Dexamethasone
Topics
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal, Humanized (administration & dosage)
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Dexamethasone (administration & dosage)
  • Humans
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (drug therapy, metabolism, mortality, pathology)
  • Recurrence
  • Sialic Acid Binding Ig-like Lectin 2 (metabolism)
  • Treatment Outcome
  • Vincristine (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: